Short Interest Update on Oculus Innovative Sciences (OCLS)

Oculus Innovative Sciences (OCLS) : The conviction of the bears is waning as is visible by the drop in the short positions from Jul 29, 2016, to August 15, 2016. The total outstanding shorts decreased from 116,433 to 99,141 shares, with 4 days to go before the expiry. The short open interest has decreased by -14.9%, amounting to a reduction of -17,292 shares. Only a handful of traders believe that the stock has a large downside from current levels, as seen in the low short interest of 2.4% of the float of the company. The average daily volume of the stock is 28,256 shares. The short interest information was released on Wednesday Aug 24th after the market close.

Oculus Innovative Sciences (NASDAQ:OCLS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.35 and $4.20 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.75. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.55, notching a gain of 14.32% for the day. The total traded volume was 843,374 . The stock had closed at $3.98 on the previous day.


In a related news, Schutz James J, CEO of Oculus Innovative Sciences, Inc., executed a transaction worth $4,860 on August 15, 2016. A total of 1,328 shares were purchased at an average price of $3.66. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Oculus Innovative Sciences, Inc. is a specialty device and pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in both humans and animals. The Company offers wound care products which are sold into the human and animal healthcare markets in the United States, Mexico and Europe. The Company also operates a microbiology contract testing laboratory division that provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs, as well as testing of products and the Companys products. The Companys key technology, Microcyn is based on electrically charged oxychlorine small molecules designed to target a range of pathogens that cause disease. The Company completed Phase II trials for Microcyn technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *